A-1155463

Name: A-1155463
Brand: MedChemExpress
SKU: HY-19725
Rating: 5.0 (23 reviews)

Art. -Nr.: HY-19725 Reinheit: 98.97%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

A-1155463, a chemical probe, is a highly potent and selective BCL-XL inhibitor with an EC₅₀ of 70 nM in Molt-4 cell. A-1155463 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

CAS. Nr. : 1235034-55-5

Größe	Verfügbarkeit	Menge

Kostenlose Probe (0.1 - 0.2 mg)	Jetzt bewerben
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	Auf Lager	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	Auf Lager	Estimated Time of Arrival: December 31
Solid
5 mg	Auf Lager	Estimated Time of Arrival: December 31
10 mg	Auf Lager	Estimated Time of Arrival: December 31
50 mg	Auf Lager	Estimated Time of Arrival: December 31
100 mg	Auf Lager	Estimated Time of Arrival: December 31
200 mg	Angebot einholen
500 mg	Angebot einholen

or Massenanfrage

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

This product is a controlled substance and not for sale in your territory.

Kundenbewertung

Based on 23 publication(s) in Google Scholar

23 Publications Citing Use of MCE A-1155463

Cell Proliferation/Viability Assay

Bio/Physico-chemical Assay

Flow Cytometry

: A-1155463 purchased from MedChemExpress. Usage Cited in: Leukemia. 2025 Dec 19. [Abstract]; A-1155463 (1-100 nM; 48 h) dose-dependently induced lethality in PD AML cells.

: A-1155463 purchased from MedChemExpress. Usage Cited in: J Hematol Oncol. 2020 Jul 16;13(1):95. [Abstract]; The viability of DFTL-28776 PDX cells was determined after A-1155463 (0.001-10 μM; 24 h) treatment.

: A-1155463 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2019 May 21;10(6):395. [Abstract]; U87, U251, H1299, and A549 cells were treated with KPT-330 (1 μM) for 24 h and further with A-1155463 (1 μM; 24 h), then subjected to western blot or flow cytometry analysis for the sub-G1 phase.

: A-1155463 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2019 May 21;10(6):395. [Abstract]; A-1331852 (1 μM; 48 h). Cell viability was measured by the MTT assay.

: A-1155463 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2019 May 21;10(6):395. [Abstract]; The mitochondrial membrane potential in U251 cells treated with A-1155463 (1 μM; 24 h) was measured by flow cytometry.

Spezialitätsempfehlungen

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Alle Bcl-2 Family Isoform-spezifische Produkte anzeigen:

Alle Isoformen anzeigen

Bcl-2 Bcl-xL Bcl-W Mcl-1 Bfl-1 Bcl-B Bax Bak Bim BNIP3 Bad

Biologische Aktivität
Protokoll
Reinheit & Dokumentation
Verweise
Kundenbewertung

Beschreibung

IC₅₀ & Target^[2]

Bcl-xL

0.01 nM (Ki)

Bcl-2

80 nM (Ki)

Cellular Effect

Cell Line	Type	Value	Description	References
DMS-79	EC₅₀	1.44 μM Compound: A-1155463	Antiproliferative activity against human DMS 79 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human DMS 79 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
EOL1	EC₅₀	2.25 μM Compound: A-1155463	Antiproliferative activity against human EOL1 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human EOL1 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
GDM-1	EC₅₀	1.17 μM Compound: A-1155463	Antiproliferative activity against human GDM-1 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human GDM-1 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
HEL	EC₅₀	0.12 μM Compound: A-1155463	Antiproliferative activity against human HEL harboring JAK2 V617F mutant assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human HEL harboring JAK2 V617F mutant assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
HL-60	EC₅₀	> 5 μM Compound: A-1155463	Antiproliferative activity against human HL-60 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human HL-60 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
KG-1	EC₅₀	> 5 μM Compound: A-1155463	Antiproliferative activity against human KG-1 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human KG-1 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
Kasumi 1	EC₅₀	0.011 μM Compound: A-1155463	Antiproliferative activity against human Kasumi 1 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human Kasumi 1 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
ML-2	EC₅₀	> 5 μM Compound: A-1155463	Antiproliferative activity against human ML-2 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human ML-2 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
MOLM-13	EC₅₀	> 5 μM Compound: A-1155463	Antiproliferative activity against human MOLM-13 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human MOLM-13 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
MOLM-16	EC₅₀	> 5 μM Compound: A-1155463	Antiproliferative activity against human MOLM16 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human MOLM16 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
MOLT-4	EC₅₀	70 nM Compound: 32; A-1155463	Cytotoxicity against human Bcl-XL dependant MOLT4 cells by cell based assay Cytotoxicity against human Bcl-XL dependant MOLT4 cells by cell based assay	[PMID: 26988306]
MOLT-4	EC₅₀	70 nM Compound: A-1155463	Antiproliferative activity against Bcl-xl dependent human MOLT-4 cells assessed as reduction in cell viability by measuring effect concentration by CellTiter-Glo reagent based assay Antiproliferative activity against Bcl-xl dependent human MOLT-4 cells assessed as reduction in cell viability by measuring effect concentration by CellTiter-Glo reagent based assay	[PMID: 25787766]
MOLT-4	EC₅₀	> 5000 nM Compound: A-1155463	Antiproliferative activity against Bcl-2 dependent human MOLT-4 cells assessed as reduction in cell viability by measuring effect concentration by CellTiter-Glo reagent based assay Antiproliferative activity against Bcl-2 dependent human MOLT-4 cells assessed as reduction in cell viability by measuring effect concentration by CellTiter-Glo reagent based assay	[PMID: 25787766]
MOLT-4	IC₅₀	6.2 nM Compound: A-1155463	Cytotoxicity against human MOLT-4 cells assessed as cell growth inhibition incubated for 72 hrs Cytotoxicity against human MOLT-4 cells assessed as cell growth inhibition incubated for 72 hrs	[PMID: 35182816]
MV4-11	EC₅₀	> 5 μM Compound: A-1155463	Antiproliferative activity against human MV4-11 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human MV4-11 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
NCI-H1048	EC₅₀	> 10 μM Compound: A-1155463	Antiproliferative activity against human NCI-H1048 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human NCI-H1048 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
NCI-H1417	EC₅₀	0.007 μM Compound: A-1155463	Antiproliferative activity against human NCI-H1417 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human NCI-H1417 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
NCI-H146	EC₅₀	0.065 μM Compound: 17, A-1155463	Cytotoxicity against BCL-XL-dependent human NCI-H146 cells in presence of 10% human serum incubated for 48 hrs by Cell titerGlo reagent based assay Cytotoxicity against BCL-XL-dependent human NCI-H146 cells in presence of 10% human serum incubated for 48 hrs by Cell titerGlo reagent based assay	[PMID: 25313317]
NCI-H1836	EC₅₀	0.015 μM Compound: A-1155463	Antiproliferative activity against human NCI-H1836 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human NCI-H1836 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
NCI-H187	EC₅₀	0.18 μM Compound: A-1155463	Antiproliferative activity against human NCI-H187 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human NCI-H187 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
NCI-H211	EC₅₀	1.35 μM Compound: A-1155463	Antiproliferative activity against human NCI-H211 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human NCI-H211 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
NCI-H345	EC₅₀	> 10 μM Compound: A-1155463	Antiproliferative activity against human NCI-H345 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human NCI-H345 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
NCI-H446	EC₅₀	0.2 μM Compound: A-1155463	Antiproliferative activity against human NCI-H446 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human NCI-H446 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
NCI-H69	EC₅₀	3.2 μM Compound: A-1155463	Antiproliferative activity against human NCI-H69 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human NCI-H69 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
NCI-H889	EC₅₀	6.31 μM Compound: A-1155463	Antiproliferative activity against human NCI-H889 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human NCI-H889 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
NOMO-1	EC₅₀	> 5 μM Compound: A-1155463	Antiproliferative activity against human NOMO-1 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human NOMO-1 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
OCI-AML-3	EC₅₀	> 5 μM Compound: A-1155463	Antiproliferative activity against human OCI-AML-3 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human OCI-AML-3 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
OCI-AML-5	EC₅₀	> 5 μM Compound: A-1155463	Antiproliferative activity against human OCI-AML5 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human OCI-AML5 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
OCI-AML2	EC₅₀	> 5 μM Compound: A-1155463	Antiproliferative activity against human OCI-AML2 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human OCI-AML2 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
Platelet	IC₅₀	7.1 nM Compound: A-1155463	Cytotoxicity against human platelets assessed as cell growth inhibition incubated for 24 hrs Cytotoxicity against human platelets assessed as cell growth inhibition incubated for 24 hrs	[PMID: 35182816]
RS4-11	EC₅₀	> 5 μM Compound: 32; A-1155463	Cytotoxicity against human Bcl-2 dependant RS4:11 cells by cell based assay Cytotoxicity against human Bcl-2 dependant RS4:11 cells by cell based assay	[PMID: 26988306]
SET-2	EC₅₀	0.08 μM Compound: A-1155463	Antiproliferative activity against human SET2 harboring JAK2 V617F mutant assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human SET2 harboring JAK2 V617F mutant assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
SIG-M5	EC₅₀	> 5 μM Compound: A-1155463	Antiproliferative activity against human SIG-M5 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human SIG-M5 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
SKM-1	EC₅₀	> 5 μM Compound: A-1155463	Antiproliferative activity against human SKM-1 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human SKM-1 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
THP-1	EC₅₀	> 5 μM Compound: A-1155463	Antiproliferative activity against human THP-1 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human THP-1 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]

In Vitro

A-1155463 shows picomolar binding affinity to BCL-X_L (K_i＜0.01 nM), and >1000-fold weaker binding to BCL-2 (K_i= 80 nM) and related proteins BCL-W (K_i= 19 nM) and MCL-1 (K_i> 440 nM) ^[2].
A-1155463 demonstrates strong growth inhibition of over half of the colorectal cell lines as defined by EC₅₀ values ≤0.5 μM in the presence of 10 % FBS^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

A-1155463 caused a mechanism-based and reversible thrombocytopenia in mice and inhibited H146 small cell lung cancer xenograft tumor growth in vivo following multiple doses^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molekulargewicht

669.79

Formel

C₃₅H₃₂FN₅O₄S₂

CAS. Nr.

1235034-55-5

Appearance

Solid

Color

Off-white to yellow

SMILES

O=C(C1=C(CCCOC2=CC=C(C#CCN(C)C)C=C2F)SC(N3CC4=C(C=CC=C4C(NC5=NC6=CC=CC=C6S5)=O)CC3)=N1)O

Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 50 mg/mL (74.65 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.4930 mL	7.4650 mL	14.9301 mL
5 mM	0.2986 mL	1.4930 mL	2.9860 mL
10 mM	0.1493 mL	0.7465 mL	1.4930 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner
Verdünnungsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (3.73 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (3.73 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (3.73 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Reinheit & Dokumentation

Purity: 99.60%

Select Batch:

Data Sheet (276 KB) SDS (393 KB)

COA (249 KB) HNMR (178 KB) LCMS (97 KB)

Handling Instructions (2659 KB)

Verweise

[1]. Leverson JD, et al. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Sci Transl Med.?2015 Mar 18;7(279):279 [Content Brief]

[2]. Tao ZF, et al. Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity. ACS Med Chem Lett. 2014 Aug 26;5(10):1088-93. [Content Brief]

[3]. Zhang H, et al. Genomic analysis and selective small molecule inhibition identifies BCL-X(L) as a critical survival factor in a subset of colorectal cancer. Mol Cancer. 2015 Jul 2;14:126. [Content Brief]

Tierverwaltung
^[2]

Mice: Following a single 5 mg/kg IP dose of A-1155463 in nontumor bearing SCID-Beige mice, platelet counts fell dramatically as measured at 6 h postdose and then rebounded to normal levels within 72 h. A-1155463 is then administered to SCID-Beige mice that had been inoculated with BCL-XL-dependent H146 tumor cells with a daily dose at 5 mg/kg IP for 14 days^[2].

MCE hat die Genauigkeit dieser Methoden nicht unabhängig bestätigt. Sie dienen nur als Referenz.

Verweise

[1]. Leverson JD, et al. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Sci Transl Med.?2015 Mar 18;7(279):279 [Content Brief]

[2]. Tao ZF, et al. Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity. ACS Med Chem Lett. 2014 Aug 26;5(10):1088-93. [Content Brief]

[3]. Zhang H, et al. Genomic analysis and selective small molecule inhibition identifies BCL-X(L) as a critical survival factor in a subset of colorectal cancer. Mol Cancer. 2015 Jul 2;14:126. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.4930 mL	7.4650 mL	14.9301 mL	37.3251 mL
	5 mM	0.2986 mL	1.4930 mL	2.9860 mL	7.4650 mL
	10 mM	0.1493 mL	0.7465 mL	1.4930 mL	3.7325 mL
	15 mM	0.0995 mL	0.4977 mL	0.9953 mL	2.4883 mL
	20 mM	0.0747 mL	0.3733 mL	0.7465 mL	1.8663 mL
	25 mM	0.0597 mL	0.2986 mL	0.5972 mL	1.4930 mL
	30 mM	0.0498 mL	0.2488 mL	0.4977 mL	1.2442 mL
	40 mM	0.0373 mL	0.1866 mL	0.3733 mL	0.9331 mL
	50 mM	0.0299 mL	0.1493 mL	0.2986 mL	0.7465 mL
	60 mM	0.0249 mL	0.1244 mL	0.2488 mL	0.6221 mL

A-1155463 Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

A-11554631235034-55-5A1155463A 1155463Bcl-2 FamilyInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Produktname			Requested Quantity *
Name des Antragstellers *			Anrede
E-Mail-Addresse *			Telefonnummer *
Department			Name der Organisation *
City			Bundesland
Country or Region *
Bemerkungen

Produktname			Lot #
Name des Antragstellers *			E-Mail-Addresse *
Telefonnummer			Department *
Name der Organisation *			Country or Region *
Bemerkungen

Name
Email *

	Sorry, but the email address you supplied was invalid.

A-1155463

Kundenbewertung

A-1155463 Related Antibodies

23 Publications Citing Use of MCE A-1155463

Spezialitätsempfehlungen

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Alle Bcl-2 Family Isoform-spezifische Produkte anzeigen:

Biologische Aktivität

Protokoll

Reinheit & Dokumentation

Verweise

Kundenbewertung

A-1155463 Related Antibodies

Molaritätsrechner

Verdünnungsrechner

Complete Stock Solution Preparation Table

A-1155463 Related Classifications

Keywords:

Ihre kürzlich angesehenen Produkte:

Kundenbewertung

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report